CA3001847A1 - Cysteine reactive probes and uses thereof - Google Patents

Cysteine reactive probes and uses thereof Download PDF

Info

Publication number
CA3001847A1
CA3001847A1 CA3001847A CA3001847A CA3001847A1 CA 3001847 A1 CA3001847 A1 CA 3001847A1 CA 3001847 A CA3001847 A CA 3001847A CA 3001847 A CA3001847 A CA 3001847A CA 3001847 A1 CA3001847 A1 CA 3001847A1
Authority
CA
Canada
Prior art keywords
cysteine
protein
containing protein
small molecule
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3001847A
Other languages
English (en)
French (fr)
Inventor
Benjamin F. Cravatt
Keriann M. BACKUS
Bruno E. Correia
Megan M. Blewett
John R. TEIJARO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CA3001847A1 publication Critical patent/CA3001847A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01042—Isocitrate dehydrogenase (NADP+) (1.1.1.42)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01023—Protein-arginine N-methyltransferase (2.1.1.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22061—Caspase-8 (3.4.22.61)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22063—Caspase-10 (3.4.22.63)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3001847A 2015-10-22 2016-10-21 Cysteine reactive probes and uses thereof Pending CA3001847A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562244881P 2015-10-22 2015-10-22
US62/244,881 2015-10-22
US201662345710P 2016-06-03 2016-06-03
US62/345,710 2016-06-03
PCT/US2016/058308 WO2017070611A1 (en) 2015-10-22 2016-10-21 Cysteine reactive probes and uses thereof

Publications (1)

Publication Number Publication Date
CA3001847A1 true CA3001847A1 (en) 2017-04-27

Family

ID=58558160

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3001847A Pending CA3001847A1 (en) 2015-10-22 2016-10-21 Cysteine reactive probes and uses thereof

Country Status (5)

Country Link
US (2) US10670605B2 (https=)
EP (1) EP3365686A4 (https=)
JP (1) JP6953400B2 (https=)
CA (1) CA3001847A1 (https=)
WO (1) WO2017070611A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10782295B2 (en) 2013-08-13 2020-09-22 The Scripps Research Institute Cysteine-reactive ligand discovery in proteomes
JP6953400B2 (ja) * 2015-10-22 2021-10-27 ザ スクリプス リサーチ インスティテュート システイン反応性プローブとその使用
JP7039489B2 (ja) 2016-05-18 2022-03-22 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
WO2017210600A1 (en) * 2016-06-03 2017-12-07 The Scripps Research Institute Compositions and methods of modulating immune response
IL268101B2 (en) 2017-01-18 2024-08-01 Scripps Research Inst Photoreactive ligands and their uses
KR20190126074A (ko) * 2017-02-03 2019-11-08 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 레티쿨론 4를 억제하기 위한 조성물 및 방법
MX2019009199A (es) * 2017-02-03 2019-10-21 Univ California Composiciones y métodos para modular ppp2r1a.
WO2018144869A1 (en) * 2017-02-03 2018-08-09 The Regents Of The University Of California Compositons and methods for modulating uba5
US20200278355A1 (en) * 2017-09-27 2020-09-03 The Scripps Research Institute Conjugated proteins and uses thereof
WO2019067733A1 (en) * 2017-09-27 2019-04-04 Vividion Therapeutics, Inc. COMPOUNDS AND METHODS FOR MODULATING PROTEIN DEGRADATION
WO2019075386A1 (en) 2017-10-13 2019-04-18 The Regents Of The University Of California MODULATORS OF MTORC1
HRP20230377T1 (hr) 2017-11-15 2023-06-23 Mirati Therapeutics, Inc. Inhibitori mutacije kras g12c
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
WO2019113724A1 (zh) * 2017-12-11 2019-06-20 广州君赫生物科技有限公司 双硫仑的新应用
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
WO2020055761A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
CN113164418A (zh) 2018-12-05 2021-07-23 米拉蒂治疗股份有限公司 组合疗法
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
US12366579B2 (en) 2019-03-21 2025-07-22 University Of Virginia Patent Foundation Sulfur-heterocycle exchange chemistry and uses thereof
EP4010459A4 (en) * 2019-08-05 2023-09-06 Bridgene Biosciences, Inc. Method for proteome-wide discovery of covalent ligands and compositions thereof
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
EP4045920A4 (en) * 2019-10-15 2023-10-11 Jnana Therapeutics Inc. INTERACTION DISCOVERY PLATFORM WITH A REACTIVE AFFINITY PROBE
CA3161949A1 (en) * 2019-10-16 2021-04-22 The Scripps Research Institute An activity-guided map of electrophile-cysteine interactions in primary human immune cells
US20240123078A1 (en) * 2019-10-16 2024-04-18 Vividion Therapeutics, Inc. Compounds and methods for modulating immune-related proteins
CN111063389B (zh) * 2019-12-04 2021-10-29 浙江工业大学 一种基于深度卷积神经网络的配体绑定残基预测方法
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
WO2022056307A1 (en) 2020-09-11 2022-03-17 Mirati Therapeutics, Inc. Crystalline forms of a kras g12c inhibitor
CN112255396A (zh) * 2020-10-15 2021-01-22 南开大学 一种测量小分子药物抑制蛋白核酸互作的单分子力学方法
WO2022132200A1 (en) 2020-12-15 2022-06-23 Mirati Therapeutics, Inc. Azaquinazoline pan-kras inhibitors
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
WO2022240966A1 (en) * 2021-05-11 2022-11-17 Opna Immuno-Oncology Sa Compounds and methods for yap/tead modulation and indications therefor
WO2023092133A1 (en) * 2021-11-22 2023-05-25 The Scripps Research Institute Stereoselective covalent ligands for oncogenic and immunological proteins
US20260079154A1 (en) * 2022-09-12 2026-03-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Composition, device, system, and methods for detecting environmental toxicants
US20260103438A1 (en) * 2022-09-28 2026-04-16 The General Hospital Corporation Probes and methods to identify ligandable fatty acylation sites for therapeutic target identification
CN116790698B (zh) * 2023-06-21 2024-06-18 南京大学 基于氧化脱羧酶的硫醛合成方法及其应用
WO2025182683A1 (ja) * 2024-02-29 2025-09-04 国立大学法人 東京大学 タンパク質の活性／反応性部位の、活性／反応性の評価方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344330B1 (en) 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
EP1185632A1 (en) * 1999-06-10 2002-03-13 PHARMACIA & UPJOHN COMPANY Caspase-8 crystals, models and methods
AU2573102A (en) * 2000-11-21 2002-06-03 Sunesis Pharmaceuticals Inc An extended tethering approach for rapid identification of ligands
WO2005118833A2 (en) 2004-06-01 2005-12-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with sterile-alpha motif and leucine zipper containing kinase (zak)
US7935479B2 (en) 2004-07-19 2011-05-03 Cell Biosciences, Inc. Methods and devices for analyte detection
US8314215B2 (en) * 2006-08-04 2012-11-20 The Board Of Trustees Of The Leland Stanford Junior University Mild chemically cleavable linker system
JPWO2008029924A1 (ja) * 2006-09-08 2010-01-21 大日本住友製薬株式会社 環状アミノアルキルカルボキサミド誘導体
US20090068107A1 (en) 2006-10-02 2009-03-12 The Scripps Research Institute Enzyme regulating ether lipid signaling pathways
CN101219219B (zh) * 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
EP1947193A1 (en) 2007-01-17 2008-07-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Screening method for anti-diabetic compounds
CA2679643A1 (en) * 2007-03-09 2008-09-18 The University Of British Columbia Procaspase 8-mediated disease targeting
EP2254574A1 (en) * 2008-02-26 2010-12-01 Ludwig-Maximilians-Universität München Beta-lactones as antibacterial agents
US9907828B2 (en) * 2012-06-22 2018-03-06 The University Of Vermont And State Agricultural College Treatments of oxidative stress conditions
EP3004141A4 (en) 2013-06-03 2017-05-31 Acetylon Pharmaceuticals, Inc. Histone deacetylase ( hdac) biomarkers in multiple myeloma
US10782295B2 (en) 2013-08-13 2020-09-22 The Scripps Research Institute Cysteine-reactive ligand discovery in proteomes
US10034892B2 (en) 2014-08-21 2018-07-31 Srx Cardio, Llc Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity
JP6953400B2 (ja) * 2015-10-22 2021-10-27 ザ スクリプス リサーチ インスティテュート システイン反応性プローブとその使用
IL268101B2 (en) 2017-01-18 2024-08-01 Scripps Research Inst Photoreactive ligands and their uses

Also Published As

Publication number Publication date
US10670605B2 (en) 2020-06-02
EP3365686A1 (en) 2018-08-29
JP6953400B2 (ja) 2021-10-27
US20170115303A1 (en) 2017-04-27
WO2017070611A1 (en) 2017-04-27
US20200292555A1 (en) 2020-09-17
EP3365686A4 (en) 2019-03-27
JP2019501363A (ja) 2019-01-17

Similar Documents

Publication Publication Date Title
US20200292555A1 (en) Cysteine reactive probes and uses thereof
US20220214355A1 (en) Sulfur-heterocycle exchange chemistry and uses thereof
US10859585B2 (en) Lipid probes and uses thereof
Ulrich et al. Ubiquitin signalling in DNA replication and repair
CA3195950A1 (en) Compounds for targeted protein degradation of kinases
US20210255193A1 (en) Lysine reactive probes and uses thereof
AU2018211066B2 (en) Photoreactive ligands and uses thereof
US20240400542A1 (en) Sulfonyl-triazoles useful as covalent kinase ligands
Hashimoto et al. Detection of chemical engagement of solute carrier proteins by a cellular thermal shift assay
Sun et al. Recent advances in proteome‐wide label‐free target deconvolution for bioactive small molecules
Xu et al. A comparison of two stability proteomics methods for drug target identification in OnePot 2D format
Sameshima et al. Discovery of an irreversible and cell-active BCL6 inhibitor selectively targeting Cys53 located at the protein–protein interaction interface
Pei et al. Exploring protein S-palmitoylation: mechanisms, detection, and strategies for inhibitor discovery
Jung et al. Discovery of non-cysteine-targeting covalent inhibitors by activity-based proteomic screening with a cysteine-reactive probe
Gunasekaran et al. Development of a polo-like kinase-1 polo-box domain inhibitor as a tumor growth suppressor in mice models
US20220251085A1 (en) Cysteine binding compositions and methods of use thereof
Kumar et al. Chemically targeting the redox switch in AP1 transcription factor ΔFOSB
WO2019067741A1 (en) CONJUGATED PROTEINS AND USES THEREOF
WO2022221451A2 (en) Sulfonyl-triazole compounds useful as ligands and inhibitors of prostaglandin reductase 2
Bravo et al. Integral solvent-induced protein precipitation for target-engagement studies in Plasmodium falciparum
US20240131032A1 (en) An activity-guided map of electrophile-cysteine interactions in primary human immune cells
WO2024097262A1 (en) Chemoproteomic capture of rna binding activity in living cells
US20240123078A1 (en) Compounds and methods for modulating immune-related proteins
Sebastian Leveraging HSF1 chemical-genetic tools to elucidate mechanisms of proteostasis
Ward Tool development to study ubiquitination machinery

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211019

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241004

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250328

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250610

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251010

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251209